SK Bioscience's stock price is going downhill day after day after the upper limit on the listing date.
According to the Korea Exchange, on the 26th, SK Biosciences finished trading at 132,000 won, down 2.94% from the previous trading day.
SK Bioscience, which has been selected as one of the major IPOs in the first half of this year, achieved a record-breaking sales of 63 trillion won in margin.
Following the enthusiasm for subscription, the initial price of the listing date was doubled that of the public offering price, and it entered the stock market as a so-called'dasang' that soared to the upper limit.
However, since the 19th, the second day of listing, the stock price has fallen for six consecutive trading days.
During this period, the stock price fell 21.89%, approaching the initial listing date of 130,000 won.
In the midst of this, individual investors steadily bought SK Biosciences, and individuals net bought 29.8 billion won worth of the upper limit of 169,000 won on the first day of listing.
In addition, it closed down 1.48%, but net purchase of KRW 176.7 billion the day after listing, when the closing price remained in the 160,000 KRW range.
In particular, on the second day of listing, the stock price rose to 190,000 won during the day.
In this way, the net purchase amount of SK Biosciences by individuals during the initial two days of listing amounted to KRW 197.7 billion.
For two days, the ants received net sales worth 136.3 billion won and 43 billion won, respectively, at the peak of foreigners and institutions.
However, the stock price of SK Bioscience plunged 13.51% on the 3rd day of listing and fell to 140,000 won, then continued to decline and fell to 132,000 won on the 26th.
During this period, individuals continued to have a buying advantage except on the 24th, which showed a slight (3.9 billion won) selling advantage.
The total amount of net purchase for 7 trading days after listing is 235.9 billion won.
It can be estimated that there are a large number of individual investors who are buying and holding SK Bioscience at their peak.
However, the stock price is still more than double the offering price of 65,000 won, so investors who have received the offer for offering stock are making profits.
Like SK Bioscience, there is a recurring phenomenon in which private investors' buying trend in the early stages of listing of popular public offering stocks is rushing.
Looking at individual net purchases during the initial 7 trading days of listing, SK Biopharm is KRW 582.3 billion, Kakao Games KRW 372.2 billion, and Big Hit KRW 463.7 billion.
However, both of these stocks surged immediately after listing and turned to a downtrend, and have yet to recover to the initial level of listing.